Douglas Hornick, MD
Clinical Professor
Biography
Dr. Hornick’s research focuses on chronic lung infections. He has prior experience as an investigator in the basic mechanisms of the interaction of Gram-negative bacterial with the airway epithelium. He has participated as a local investigator in bronchiectasis trials and multiple adult CF clinical trials. More recently he has been actively facilitating participation in translational projects related to lung infections. One example includes an investigator-initiated trial to examine the element Gallium effect on chronic Pseudomonas aeruginosa infection in patients with bronchiectasis.
| PCORI Oregon Health & Sciene University/1012819_IOWA | Multicenter randomized pragmatic clinical trial comparing two- versus three-antibiotic therapy for pulmonary M avium complex disease. |
| Insmed Inc/INS-416 | ARIS & ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC) |
| Paratek Pharmaceuticals/PTK0796-NTM-20203 | Phase 2, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Omadacycline in Adult Subjects with Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus complex (MABc). |
| Insmed Inc/INS1007-301 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study. |
